Determination of the Effective Therapeutic Dose of Intrathecal Sufentanil for Extracorporeal Shock Wave Lithotripsy
Wei C. Lau, MD*, Carmen R. Green, MD*, Gary J. Faerber, MD †, Alan R. Tait, PhD*, and Julie A. Golembiewski, PharmD* Departments of *Anesthesiology and †Surgery (Section of Urology), University of Michigan Medical Center, Ann Arbor, Michigan Intrathecal (IT) sufentanil provides effective analgesia for extracorporeal shock wave lithotripsy. However, the optimal dose of sufentanil has not been established. We designed a prospective, randomized, double-blinded study to determine the optimal dose of IT sufentanil. Sixty men were randomizedtoreceive12.5,15,17.5,or20 gofITsufentanil(nϭ 15 for each group) via a combined spinal epidural technique. Inadequate analgesia was treated with IV propofol, and the epidural was activated for a pain score greater than 6 on a 10-pointverbalanalogpainscale.Intraoperativeandpostoperative visual analog pain scale scores were significantly higher in the 12.5-g group compared with 20-g group (3.2 Ϯ 1.6 vs 1.6 Ϯ 1.2, P Ͻ 0.05, and 1.1 Ϯ 0.5 vs. 0.5 Ϯ 0.4, P Ͻ 0.05, respectively). The smaller-dosage groups of IT sufentanil required significantly more supplemental boluses of propofol compared with the 20-g group (67%, 53%, and 40% vs 6%, respectively, P Ͻ 0.05). However, pruritus was significantly diminished in the smaller-dosage groups compared with the 20-g group (55%, 60%, and 67% vs 100%, P Ͻ 0.05). The time to discharge was significantly shorter in the 15-g group compared with the 20-g group (84 Ϯ 40 min vs 126 Ϯ 48 min, P Ͻ 0.05). These results suggest that 15 g of IT sufentanil may be the optimal IT dose for patients undergoing extracorporeal shock wave lithotripsy. Implications: Many anesthetic techniques are used for extracorporeal shock wave lithotripsy (ESWL). We have previously shown that intrathecal sufentanil was effective for ESWL, but was associated with a high incidence of itching. We tested 60 patients in four spinal sufentanil dose groups and found that doses of 15 and 17.5 g provided the most effective analgesia with the fewest side effects for ESWL, with only mild itching.
(Anesth Analg 1999;89:889-92) G eneral, epidural, and spinal anesthetics have been successfully used for extracorporeal shock wave lithotripsy (ESWL) (1) (2) (3) . Intrathecal (IT) sufentanil provides effective analgesia for ESWL for nephrolithiasis using the first generation Dornier HM3 lithotripter (4 -6) . In a previous study, 20 g of IT sufentanil provided excellent analgesia and earlier discharge when compared with IT lidocaine but was associated with a high incidence of pruritus (6) . This study was designed to prospectively determine the optimal therapeutic dose of IT sufentanil for ESWL. We hypothesized that 20 g of IT sufentanil would provide superior analgesia with similar side effects compared with smaller doses of IT sufentanil for patients undergoing ESWL procedures.
Methods
This prospective, randomized, double-blinded study was approved by the institutional review board. Sixty ASA physical status I-III, 18-to 70-yr-old men, who were scheduled for unilateral ESWL using the Dornier HM3 for nephrolithiasis, were enrolled in this study after providing written, informed consent. Patients were randomized using a random number scheme to receive either 12.5, 15, 17.5, or 20 g of IT sufentanil (n ϭ 15 for each group). Exclusion criteria included allergic reaction to opioids, bleeding disorder, significant heart disease (valvular heart disease, ischemic heart disease, ejection fraction Ͻ 40%), any contraindications to regional anesthesia, psychiatric impairment, and a significant history of opioid or substance abuse.
The different doses of sufentanil were diluted with sterile, normal saline to a volume of 2 mL in a syringe labeled "study drug". During the preoperative period, patients were instructed to assess the severity of their pain using a 10-point verbal analog pain scale (VAPS), 0 ϭ no pain, 10 ϭ worst pain imaginable. In the preoperative holding room, all study patients received emulsified diazepam 1-5 mg IV in a titrated dose by the anesthesiologist to provide anxiolysis with minimal sedation.
In the operating room, oxygen 2-4 L/min was delivered via a nasal cannula, and standard anesthetic monitors were applied to the patient. The patients' respiratory rates and end-tidal CO 2 were also monitored. IT sufentanil was administered via the combined spinal epidural technique (7). The combined spinal epidural was performed with the patient flexed in the lateral decubitus position using a midline technique at the L1-2 interspace. The epidural space was located using strict aseptic technique with an 18-gauge Tuohy needle with the "loss of resistance" technique. A 25-gauge, 12.7-cm Whitacre spinal needle was passed through the epidural needle into the subarachnoid space. Before injection, cerebral spinal fluid was aspirated to confirm IT administration. The spinal needle was withdrawn, and the epidural catheter was placed through the epidural needle. Sensory changes were determined using alcohol swab and pin prick. Motor blockade of the lower extremities was determined using Bromage's scale. Patients were asked to assess their intraoperative VAPS score every 15 min, as previously instructed. No supplemental IV opioids were administered during the intraoperative period. If mild discomfort was observed (VAPS score 3-6), the procedure was stopped, and supplemental IV propofol in 10-to 20-mg increments was administered as necessary. In the case of moderate-to-severe pain (VAPS score Ͼ 6), 2% chloroprocaine (10 -20 mL) was administered to achieve an adequate segmental nerve block for ESWL. Failure to provide an adequate level of intraoperative anesthesia was considered to be a "failed" block and general anesthesia with propofol was instituted (laryngeal mask airway or oral intubation).
After ESWL, patients were taken to the postanesthesia care unit (PACU) Phase II for recovery and home discharge when all criteria were met (6) . Patients who required activation of epidural or general anesthesia recovered in PACU Phase I before admission to PACU Phase II. In the PACU, the epidural catheter was removed, and patients assessed their pain using the 10-point VAPS. Patients with moderate-to-severe postoperative pain (VAPS score Ͼ 6) received incremental doses of IV fentanyl 25 g, administered by the PACU nursing staff.
The duration of anesthesia (i.e., the time from entering until leaving the operating room) and the duration of the procedure (i.e., the time from starting to ending shock wave treatments) were recorded. The patients' vital signs, hemoglobin oxygen saturation, VAPS scores, and incidence of side effects (e.g., nausea, vomiting, pruritus, and sedation) were monitored and recorded intraoperatively every 15 min. Fentanyl requirements in the PACU, postoperative nausea and vomiting (PONV), pruritus, and recovery times (i.e., ambulation, voiding, and discharge) were also recorded. Nausea that persisted for more than 5 min or repeated episodes of vomiting were treated with prochlorperazine 5 mg IV. If pruritus was present, patients were asked if the severity of pruritus required treatment. Incremental doses of diphenhydramine 25 mg IV were used to treat pruritus. Postoperative side effects before the patient's discharge home and 24 h after discharge were documented to evaluate home recovery and side effects.
Sample size calculations for differences in VAPS scores were based on data from a previously published study (6) , in which sufentanil 20 g IT resulted in an intraoperative VAPS score of 1. Because we assumed that the smallest differences in VAPS scores would occur between 20 and 17.5 g and that a doubling of this score would be considered important, we calculated a sample size of 15 per dosage group (␣ ϭ 5%, ␤ ϭ 20%). Parametric data were analyzed using analysis of variance. Post hoc analysis of pairwise comparisons after the analysis of variance were made using the Tukey test, which assumes homogeneity of variances. Nonparametric data were analyzed by 2 and Fisher's exact tests, as appropriate. A P value Ͻ 0.05 was considered to be statistically significant. All data are expressed as mean Ϯ sd or percentages.
Results
The demographic characteristics are presented in Table 1 . Intraoperative VAPS scores and supplemental propofol are presented in Table 2 . Although age, ASA physical status, and height were similar among the four groups, patients in the 15-and 17.5-g groups weighed more than the 12.5-and 20-g groups (P Ͻ 0.05). There were no failed blocks, and no patient required epidural activation. There were no significant reductions in oxygen saturation among the four study groups. Intraoperative and postoperative VAPS scores were significantly different between the 12.5 and 20 g groups of IT sufentanil (3.2 Ϯ 1.6 vs 1.6 Ϯ 1.2, P Ͻ 0.05, and 1.1. Ϯ 5 vs 0.5 Ϯ 0.4, P Ͻ 0.05, respectively). The dosages of supplemental propofol in the 12.5-, 15-, and 17.5-g sufentanil groups were significantly larger when compared with the 20-g group. Two patients (13%) in the 12.5-g group required 50 g IV fentanyl for postoperative analgesia. No differences occurred among the groups in the need for oral pain medication in the PACU (Table 2) . Two patients (13%) in the 20-g group experienced PONV that required prochlorperazine 5 mg IV. There were significant differences in the incidence of pruritus among the different sufentanil dosage groups (100%, 67%, 60%, and 53%, for 20, 17.5, 15 and 12.5 g sufentanil, respectively). However, there were no differences in the frequency of IV diphenhydramine administration among the four groups. No differences were noted among the four groups in the time to p.o. intake, ambulations, or voiding. The time to discharge was significantly different among the 15-and 20-g groups of IT sufentanil (84 Ϯ 40 vs 126 Ϯ 48 min, respectively, P Ͻ 0.05).
Discussion
D'Angelo et al. (8) reported an 84% incidence of pruritus after 10 g of IT sufentanil. In our previous study (6), we reported a 27% incidence of pruritus after 20 g of IT sufentanil, whereas, in this study, all patients receiving 20 g experienced pruritus. Although it is unclear why there were differences in the incidence of pruritus between the two studies, this current study suggests that the incidence of pruritus is dose-related. Another possible explanation for the higher incidence of pruritus in the 20-g dose group was the significantly smaller dosage of propofol supplementation, because propofol has been shown to relieve pruritus produced by IT opioids (9). Despite the higher incidence of pruritus in the 20-g group, there were no differences in the requirement for IV diphenhydramine. Although not statistically different from the smaller-dosage groups, 13% of the patients in the 20-g IT sufentanil group experienced PONV that required antiemetic treatment.
IT sufentanil doses of 15-20 g were found to provide adequate analgesia for ESWL. These results are consistent with the findings of Lu et al. (10) , who demonstrated in an experimental pain model that there was no dose-dependent improvement in analgesia in the range of 12.5-50 g of IT sufentanil. These authors also reported that the incidence of side effects Values are expressed as mean Ϯ sd or n (%). ESWL ϭ extracorporeal shock wave lithotripsy, VAPS ϭ verbal analog pain scale (0 ϭ no pain, 10 ϭ worst pain imaginable), PONV ϭ postoperative nausea vomiting, P.o. ϭ per os.
a Average of all observation during the intraoperative/postanesthesia care unit period. * P Ͻ 0.05 versus 20 g intrathecal sufentanil. ANESTH ANALG AMBULATORY ANESTHESIA LAU ET AL.
was dose-dependent. Therefore, there is no evidence to suggest the use of more than the 20-g dose of IT sufentanil. As in our previous study, we used continuous monitoring of pulse oximetry, respiratory rate, and sedation level to assure patient safety. The time to void was shortest in the 15-g group, and, thus, they were discharged earlier than the 20-g group (P Ͻ 0.05). Dose-dependent urinary retention has been described with IT opioids (12, 13) . As demonstrated, the 12.5-g dose of IT sufentanil is inadequate analgesia for unilateral ESWL, as reflected by intraoperative and postoperative VAPS scores and the requirement for propofol supplementation. In addition, IV fentanyl was required to achieve adequate postoperative analgesia in the 12.5-g IT group. The increased pain and subsequent titration of fentanyl led to discharge times that were similar to those for the 20-g group. The use of propofol supplementation seemed to have no effect on the recovery profile. It is unclear if pruritus or the administration of diphenhydramine increased the length of stay, except possibly in the 20-g group, in which 100% of the patients experienced pruritus, and 40% required diphenhydramine. Discharge time in the 20-g group was increased, most likely, as a result of a dose-dependent increase in urinary retention, as reflected by the longer ambulation to void time.
Results of this study confirm that 20 g of IT sufentanil is a safe and effective anesthetic for men undergoing ESWL. Although the incidence of pruritus was high in the 20-g group, no clinical significance in the severity of pruritus was demonstrated. It appears that 15 or 17.5 g of IT sufentanil provides adequate anesthesia when combined with IV propofol. All doses of IT sufentanil were associated with pruritus, which appears to be dose-related. The lowest dose of IT sufentanil (12.5 g) did not provide consistent analgesia for ESWL, required significant supplemental propofol, and was associated with a recovery profile that was comparable to 20 g of IT sufentanil. Based on the results of this study, we now believe that 15 g of IT sufentanil is the optimal dose for unilateral ESWL in men.
